<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences & Janssen R & D, LLC to screen extensive library of compounds.

Posted by MD Biosciences on Apr 14, 2014 8:00:00 AM

MD Biosciences enters into an agreement with Janssen Research & Development, LLC to screen an extensive library of compounds with its proprietary Senerga® Phenotypic Screening Platform.


St Paul, MN (April 14, 2014) – MD Biosciences announces that it has entered into a research agreement with Janssen Research & Development, LLC, through the Janssen Incubator and a venture team focused on natural product drug discovery programs, to screen a novel and proprietary chemical library of compounds for pharmaceutically relevant activity.  MD Biosciences will apply its innovative screening platform, Senerga® Phenotypic Screening Platform for this purpose. Senerga® PSP is based on three matrices covering  pathways related to inflammatory, metabolic, cardiovascular and CNS diseases in addition to delivering preliminary toxicology data. Senerga® PSP delivers a comprehensive portfolio of phenotypic and biomarker data for each compound in the library and points towards putative mode of action of novel compounds. A dedicated scoring algorithm is used to rank compounds with regards to their activity. Pharmaceutically active compounds will be validated in dedicated disease models. The use of Senerga® PSP provides unique speed and efficiency in mining its novel chemical library.


About the Senerga® Screening Platform

MD Biosciences has in-depth expertise and data on complex programs involving mechanism of action and efficacy studies. Senerga®PSP provides a uniquely customized approach applicable to new compounds as well as for repositioning of failed or on-market drugs. Senerga® is available for collaborative development programs together with pharmaceutical and biotechnology companies.


About MD Biosciences

MD Biosciences is dedicated to the preclinical discovery and development of compounds. The company engages in collaborative partnerships and research projects with pharmaceutical and biotechnology companies world wide. MD Biosciences operates purpose-built and state-of-the-art facilities in Nes Ziona, Israel and in St. Paul, MN, USA.





The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: CRO/outsourcing, news

MD Biosciences Receives AAALAC Accreditation

Posted by MD Biosciences on Mar 19, 2014 12:59:00 PM

Wednesday, March 19, 2014, St. Paul, MN – MD Biosciences, a drug discovery and development services provider, is pleased to announce it has been give full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Accreditation for the St Paul facility was awarded following an extensive on-site assessment by representatives of the Council on Accreditation, which stated that MD Biosciences “provides and maintains an excellent program of laboratory animal care and use” with particular noteworthiness in the program alignment with quality animal care and use, comprehensive occupational health and hazard reduction, high level of attention to detail in documentation and standard operating procedures as well as staff training programs and a high level of expertise among the personnel. 


“We are very pleased to receive accreditation from AAALAC, recognizing that only 900+ institutions worldwide carry this accreditation. MD Biosciences prides itself on high standards both in scientific methods and animal care. This accreditation provides our clients assurance of our commitment to compliance with industry and regulatory guidelines for high standards of animal care and handling” said Eddie Moradian, CEO of MD Biosciences. Researchers can read further about the benefits of accreditation here.


MD Biosciences is also committed to its continuing development and expansion of services it offers its clients and partners from its multiple laboratories. In addition to specialized efficacy studies and the development of more clinically relevant models, MD Biosciences also offers its partners customized screening programs aligned with clients’ specific business goals.



 About AAALAC International

AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. AAALAC stands for the "Association for Assessment and Accreditation of Laboratory Animal Care." More than 900 companies, universities, hospitals, government agencies and other research institutions in 37 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use. These institutions volunteer to participate in AAALAC's program, in addition to complying with the local, state and federal laws that regulate animal research.



About MD Biosciences

MD Biosciences is a leading preclinical research group and contract research organization (CRO) working with biopharmaceutical and medical device companies in an effort towards progressing discovery and development programs to clinical stages. We are deeply focused on inflammatory, neurodegenerative/CNS, pain, dermal, metabolic and cardiovascular conditions with a particular emphasis on the interplay between the immune, nervous and cardiovascular systems and the conditions that arise in the cross talk between them. We bring decisive value to our clients’ programs with the extensive experience gained over many years of handling different compound classes and numerous therapeutic indications. MD Biosciences operates three state-of-the-art laboratories across the globe equipped with highly specialized infrastructure, equipment, methods and scientists with expertise in therapeutics areas. Find out more about MD Biosciences and the services offered at www.mdbiosciences.com.




The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: CRO/outsourcing, news